Dissecting aberrant functions of the ubiquitin proteasome system in the treatment-induced evolution of Mantle Cell Lymphoma
(A04)
Subject Area
Hematology, Oncology
Term
from 2016 to 2020
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 278529602
Mantle cell lymphoma (MCL) and multiple myeloma (MM) are incurable B-cell malignancies. Major treatment modalities of both entities include DNA damaging agents, proteasome inhibitors and immunomodulatory drugs (IMiDs) whose anti-tumour activities and induced resistance mechanisms critically involve the ubiquitin proteasome system (UPS). This project therefore aims to dissect aberrant functions of the UPS that contribute to treatment-induced evolution of MCL and MM and unravel their role as new therapeutic targets and biomarkers.
DFG Programme
Collaborative Research Centres
